Journal of Mahatma Gandhi University of Medical Sciences and Technology

Register      Login

VOLUME 6 , ISSUE 1 ( January-April, 2021 ) > List of Articles


Mucormycosis: A Deadly Complication of COVID-19 and Diabetes

Manu Jain, Puneet Rijhwani, Anchin Kalia, Dinesh Yadav, Ambika Tyagi

Keywords : COVID-19, Diabetes, Mucormycosis

Citation Information : Jain M, Rijhwani P, Kalia A, Yadav D, Tyagi A. Mucormycosis: A Deadly Complication of COVID-19 and Diabetes. J Mahatma Gandhi Univ Med Sci Tech 2021; 6 (1):35-38.

DOI: 10.5005/jp-journals-10057-0149

License: CC BY-NC 4.0

Published Online: 31-08-2021

Copyright Statement:  Copyright © 2021; The Author(s).


Mucormycosis is a fungal infection, caused by fungi of the order Mucorales of subphylum Mucoromycotina. It is an aggressive, life-threatening infection that is common in immunocompromised patients and diabetics. COVID-19 infection and its treatment renders the patient severely immunocompromised and can increase the risk of such secondary infections. Here, we present a case of a 62-year-old man, a known case of diabetes who was recently diagnosed as COVID-19 positive. He then complained of left eye swelling and pain, with chemosis while being on steroids and remdesivir for the COVID-19 pneumonia. He was later diagnosed with orbital cellulitis, with a possible fungal infection which was later confirmed microbiologically. The patient was started on liposomal amphotericin B and high-grade antibiotics for orbital cellulitis. The patient later succumbed to sepsis-related complications. We conclude that prompt identification of symptoms and early initiation of therapy is necessary to have a better outcome in such cases, also this case can help us be more vigilant in diabetic patients with COVID-19, in whom therapeutic agents like steroids and monoclonal antibodies should be given at lowest recommended doses.

PDF Share
  1. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41(5):634–653. DOI: 10.1086/432579.
  2. Clinical management protocol for COVID-19. [Jul; 2020]; 2020 [Ref list].
  3. COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health. [Jul; 2020]; [Ref list].
  4. Lega S, Naviglio S, Volpi S, et al. Recent insight into SARS-CoV2 immunopathology and rationale for potential treatment and preventive strategies in COVID-19. Vaccines 2020;8(2):224. DOI: 10.3390/vaccines8020224.
  5. Derouiche S, Cheradid T, Abdelmalek D, et al. Effect of COVID-19 infection on the immune system and risk of developing diabetes complications: a review. J Pharm Care 2020;8(3):133–139.
  6. Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis 2019;19(12):e405–e421. DOI: 10.1016/S1473-3099(19)30312-3.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.